Enthusiasts thought the discovery that graphene, a form of carbon, could be extracted from graphite would change the world.

AstraZeneca has reported the first phase 3 data with its next-generation complement C5 inhibitor, gefurulimab, which could give patients with generalised myasthenia gravis (gMG) a treatment option ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.